The IPO bidding window for the ₹745 crore Anand Rathi Share & Stock Brokers IPO is open today, September 23, 2025, and will close on September 25, 2025. One day before the IPO opening, the company had raised ₹220.5 crore from its anchor investors on September 22, 2025.
The Anand Rathi Share & Stock Brokers IPO is a book-building issue of ₹745 crores, comprising entirely a fresh issue of 1.80 crore shares. The price band is set between ₹393 and ₹414 per share. The basis of allotment will be finalised by September 26, 2025, and the tentative listing date on BSE and NSE is September 30, 2025.
[23-September-2025, 11:42:00]
Investor Category |
Subscription (Times) |
Qualified Institutional Buyers (QIBs) |
Nil |
Non-Institutional Investors |
0.14 |
Retail Individual Investors (RIIs) |
0.21 |
Employees |
0.69 |
Total |
0.15 |
The net proceeds from the fresh will be used towards:
As of 23 September 2025, Anand Rathi Share & Stock Brokers IPO GMP stood at ₹32. The estimated listing price is ₹446, i.e., a 7.73% gain per share over the upper price band.
Source: Business Standard Report dated 23 September 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor do we recommend or endorse trading in the grey market. |
Anand Rathi Share & Stock Brokers is a full-service brokerage firm that provides broking
services, margin trading facility and distribution of financial products under the brand ‘Anand Rathi’. Through a network of 90 branches spread across 54 cities in India, the company caters to a diverse clientele, including retail, high-net-worth individuals, ultra-high-net-worth individuals and institutions.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.